said the FDA is delaying approval of a lymphoma treatment because of manufacturing issues at a company that provides services to IDEC.
Despite the delay, the company said the application for the drug, Zevalin, was deemed approvable and no further testing is required. Clearance is being held up because of compliance questions at a so-called "fill/finish" provider.
The company's shares traded higher on the news, gaining 79 cents, or about 1%, to $63.10 on Instinet.
IDEC said it's working with the FDA and the provider to resolve the issues and remains committed to getting the treatment approved. Zevalin is a monoclonal antibody aimed at non-Hodgkin's lymphoma.